Literature DB >> 26582172

Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis.

Yan Song1, Natalia Hernandez2, Jonathan Shoag3, David S Goldfarb4, Brian H Eisner5.   

Abstract

Two previous studies (<10 patients each) have demonstrated that alkali therapy may reduce urine calcium excretion in patients with calcium oxalate nephrolithiasis. The hypothesized mechanisms are (1) a decrease in bone turnover due to systemic alkalinization by the medications; (2) binding of calcium by citrate in the gastrointestinal tract; (3) direct effects on TRPV5 activity in the distal tubule. We performed a retrospective review of patients on potassium citrate therapy to evaluate the effects of this medication on urinary calcium excretion. A retrospective review was performed of a metabolic stone database at a tertiary care academic hospital. Patients were identified with a history of calcium oxalate nephrolithiasis and hypocitraturia who were on potassium citrate therapy for a minimum of 3 months. 24-h urine composition was assessed prior to the initiation of potassium citrate therapy and after 3 months of therapy. Patients received 30-60 mEq potassium citrate by mouth daily. Inclusion criterion was a change in urine potassium of 20 mEq/day or greater, which suggests compliance with potassium citrate therapy. Paired t test was used to compare therapeutic effect. Twenty-two patients were evaluated. Mean age was 58.8 years (SD 14.0), mean BMI was 29.6 kg/m(2) (SD 5.9), and gender prevalence was 36.4% female:63.6% male. Mean pre-treatment 24-h urine values were as follows: citrate 280.0 mg/day, potassium 58.7 mEq/day, calcium 216.0 mg/day, pH 5.87. Potassium citrate therapy was associated with statistically significant changes in each of these parameters-citrate increased to 548.4 mg/day (p < 0.0001), potassium increased to 94.1 mEq/day (p < 0.0001), calcium decreased to 156.5 mg/day (p = 0.04), pH increased to 6.47 (p = 0.001). Urine sodium excretion was not different pre- and post-therapy (175 mEq/day pre-therapy versus 201 mEq/day post-therapy, p = NS). Urinary calcium excretion decreased by a mean of 60 mg/day on potassium citrate therapy-a nearly 30 % decrease in urine calcium excretion. These data lend support to the hypothesis that alkali therapy reduces urine calcium excretion.

Entities:  

Keywords:  Kidney stone; Potassium citrate; Urine calcium

Mesh:

Substances:

Year:  2015        PMID: 26582172     DOI: 10.1007/s00240-015-0819-8

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  18 in total

Review 1.  Pathophysiology and management of calcium stones.

Authors:  Sangtae Park; Margaret S Pearle
Journal:  Urol Clin North Am       Date:  2007-08       Impact factor: 2.241

2.  Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial.

Authors:  Sigrid Jehle; Henry N Hulter; Reto Krapf
Journal:  J Clin Endocrinol Metab       Date:  2012-11-15       Impact factor: 5.958

3.  Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?

Authors:  Christopher S Saigal; Geoffrey Joyce; Anga R Timilsina
Journal:  Kidney Int       Date:  2005-10       Impact factor: 10.612

4.  Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins.

Authors:  Tom Nijenhuis; Kirsten Y Renkema; Joost G J Hoenderop; René J M Bindels
Journal:  J Am Soc Nephrol       Date:  2006-01-18       Impact factor: 10.121

5.  Prevalence of kidney stones in the United States.

Authors:  Charles D Scales; Alexandria C Smith; Janet M Hanley; Christopher S Saigal
Journal:  Eur Urol       Date:  2012-03-31       Impact factor: 20.096

6.  Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis.

Authors:  P Barcelo; O Wuhl; E Servitge; A Rousaud; C Y Pak
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

7.  Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis.

Authors:  B Ettinger; C Y Pak; J T Citron; C Thomas; B Adams-Huet; A Vangessel
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

8.  Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation.

Authors:  B Hess; L Zipperle; P Jaeger
Journal:  Am J Physiol       Date:  1993-12

9.  Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol.

Authors:  F L Levy; B Adams-Huet; C Y Pak
Journal:  Am J Med       Date:  1995-01       Impact factor: 4.965

10.  Urinary Tamm-Horsfall protein increased after potassium citrate therapy in calcium stone formers.

Authors:  H A Fuselier; D M Ward; J S Lindberg; J M Allen; F E Husserl; P A Marcucci; F E Cole; J Turnipseed; J Alam; D J Kok
Journal:  Urology       Date:  1995-06       Impact factor: 2.649

View more
  6 in total

1.  Potassium citrate vs. hydrochlorothiazide to reduce urinary calcium excretion in calcium oxalate stone patients with hypercalciuria: a prospective randomized study.

Authors:  Vahid Solak; Mehmet İlker Gökce; Önder Yaman
Journal:  Int Urol Nephrol       Date:  2021-04-26       Impact factor: 2.370

2.  Safety of potassium-bearing citrate in patients with renal transplantation: A case report.

Authors:  Lin Wang; Yinglin Cui; Jianwei Zhang; Qinsheng Zhang
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

3.  Impact of potassium citrate on urinary risk profile, glucose and lipid metabolism of kidney stone formers in Switzerland.

Authors:  Anna Wiegand; Gioia Fischer; Harald Seeger; Daniel Fuster; Nasser Dhayat; Olivier Bonny; Thomas Ernandez; Min-Jeong Kim; Carsten A Wagner; Nilufar Mohebbi
Journal:  Clin Kidney J       Date:  2019-08-19

4.  Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria.

Authors:  Matthew R D'Costa; Annamaria T Kausz; Kevin J Carroll; Jóhann P Ingimarsson; Felicity T Enders; Kristin C Mara; Ramila A Mehta; John C Lieske
Journal:  Nephrol Dial Transplant       Date:  2021-12-02       Impact factor: 5.992

Review 5.  Medical therapy for nephrolithiasis: State of the art.

Authors:  Igor Sorokin; Margaret S Pearle
Journal:  Asian J Urol       Date:  2018-09-03

6.  Inhibitory effects of taraxasterol and aqueous extract of Taraxacum officinale on calcium oxalate crystallization: in vitro study.

Authors:  Mahboubeh Yousefi Ghale-Salimi; Maryam Eidi; Nasser Ghaemi; Ramezan Ali Khavari-Nejad
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.